期刊
BLOOD
卷 127, 期 26, 页码 3312-3320出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-02-629063
关键词
-
类别
资金
- National Cancer Institute, National Institutes of Health [4 P01 CA023766-37, 1 K12 CA184746-01A1, 1 P01 CA190174-01A1]
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据